背景：FAM110B 属于具有 110 序列相似性的家族 (FAM110)，位于中心体和有丝分裂纺锤体中。早期研究表明 FAM110B 与肿瘤细胞生长有关。 FAM110B 在肿瘤微环境以及泛癌微环境中的功能存在不确定性。方法：为了评估正常组织和泛癌组织内 FAM110B 表达的变化，我们结合了 TCGA 和 GTEx 数据库。使用cBioPortal数据库和GSCALite平台检查FAM110B的基因组变异和甲基化改变。采用Cox回归、Kaplan-Meier和SangerBox检查FAM110B和泛癌的临床特征和预后。相关研究的目的是调查免疫相关基因、肿瘤突变负荷、微卫星不稳定性、免疫相关基因以及免疫检查点和 FAM110B 表达之间的关联。采用ESTIMATE、EPIC、QUANTISEQ和MCPCOUNTER方法计算FAM110B表达与肿瘤免疫微环境之间的相互作用。通过单细胞数据库（TISCH和CancerSEA）分析FAM110B的免疫浸润和功能。最后，我们通过GDSC和CTRP数据库评估了FAM110B对小分子药物的敏感性。结果：FAM110B的转录和蛋白表达在不同癌症类型中存在显着差异，这对某些肿瘤的预后具有预测价值；包括脑低级别胶质瘤（LGG）、胃腺癌（STAD）、胰腺腺癌（PAAD）等。在肿瘤微环境中，FAM110B的表达水平与免疫细胞浸润、免疫检查点免疫调节基因、肿瘤突变负荷、以及微卫星在一定程度上的脆弱性。结论：本工作探讨了 FAM110B 作为预测泛癌免疫治疗反应标志物的可能性，为癌症治疗提供理论基础。版权所有 © 2024 Li、Li、Wu、Su、Su 和Guo。

Background: FAM110B belongs to the family that has a 110 sequence similarity (FAM110) and is located in the centrosome and mitotic spindle. FAM110B has been linked to tumor cell growth in earlier research. Uncertainty exists regarding FAM110B's function within the tumor microenvironment is unclear as well as pan-cancer. Methods: In order to assess the variation in FAM110B expression within normal and pan-cancer tissues, we combined the TCGA and GTEx databases. The cBioPortal database and the GSCALite platform were used to examine the variation in genome and methylation alteration of FAM110B. Cox regression, Kaplan-Meier, and SangerBox were employed to examine the clinical features and prognosis of FAM110B and pan-cancer. The purpose of the correlational research was to investigate the associations within immunerelated genes, tumor mutation burden, microsatellite instability, immune-related genes, and immunological checkpoints and FAM110B expression. ESTIMATE, EPIC, QUANTISEQ, and MCPCOUNTER methods were used to calculate the interaction among FAM110B expression as well as the tumor immune microenvironment. The immunoinfiltration and function of FAM110B were analyzed by single-cell databases (TISCH and CancerSEA). Finally, we evaluated the sensitivity of FAM110B to small-molecule medications through GDSC and CTRP databases. Results: The transcription and protein expression of FAM110B varies significantly throughout cancer types, and this has predictive value for the prognosis of some tumors; including brain lower grade glioma (LGG), stomach adenocarcinoma (STAD), pancreatic adenocarcinoma (PAAD), etc. In the tumor microenvironment, the expression level of FAM110B was associated with immune cell infiltration, immune checkpoint immune regulatory genes, tumor mutational burden, and microsatellite fragility to a certain extent. Conclusion: This work investigates the possibility of utility of FAM110B as a marker to forecast pan-cancer immunotherapy response, providing a theoretical basis for cancer therapy.Copyright © 2024 Li, Li, Wu, Su, Su and Guo.